Molecular characterization of pre-cancerous changes in cells lining the stomach could point to lesions with a greater risk of progression to cancer.

Emmanuel Volanakis, M.D., assistant professor of Pediatrics and Hematology/Oncology, was awarded a $250,000 Hyundai Hope On Wheels grant last week for his ongoing research into T-cell acute lymphoblastic leukemia (ALL), an aggressive blood cancer.

Vanderbilt investigators have combined next-generation sequencing technologies and bioinformatics analyses to screen for genome-wide genetic mutations associated with drug resistance in a series of lung cancer cell lines.

A newly identified factor regulates blood vessel growth in colorectal tumors and could be a promising target for cancer therapies.

The nuclear receptor TR3 contributes to ovarian cancer cell death in response to platinum-based chemotherapy – and may be a good target for overcoming cell resistance to certain treatments.

Robert Coffey Jr., M.D., Ingram Professor of Cancer Research at Vanderbilt University, has received a five-year, $5.2 million grant from the National Institutes of Health (NIH) to study the role of extracellular RNA (ex-RNA) in colorectal cancer.

Vanderbilt-Ingram Cancer Center investigators are receiving $1 million in breast cancer research grant funds from Susan G. Komen, the largest nonprofit foundation supporting breast cancer research.